RepCapExcel™ Boosts Gene Therapy Manufacturing Yields, Delivering Titer Gains
Abstract: Transient transfection-based AAV manufacturing continues to face an industry-wide yield ceiling, limiting scalability, increasing costs, and challenging the commercial viability of gene therapy programs. RepCapExcel™—a Catalent innovation—addresses this constraint by delivering up to 3–6X higher titers across multiple AAV serotypes without altering the therapeutic product. By enhancing production biology rather than modifying vector components, it avoids additional regulatory complexity while improving manufacturing efficiency.
These gains enable a reduced manufacturing footprint, lower cost of goods, and greater capacity to meet growing clinical and commercial demand. Extending beyond standard serotypes to engineered and next-generation capsids, RepCapExcel™ provides a flexible platform solution that supports pipeline expansion and accelerates time to market.